Friday, 10 July 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 10 July 2026
News

Next up: a weight loss implant

Posted 10 July 2026 AM

First we had injections, then we had pills. Now, Novo Nordisk has signed a deal with Californian biotech Vivani Medical to evaluate a semaglutide implant. 

In its latest move to regain the initiative against rival Eli Lilly in the GLP-1 wars, Novo will assess NPM-139, a semaglutide implant for chronic weight management that Vivani has developed using its NanoPortal platform technology. 

To see the whole article, please login

Popular

Another GM gone, successor named
Extra leave coming to pharma?
Another drug leaving Australia
Which company has the best MSLs?
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (24)

Access & Reimbursement (1)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home